CORCEPT THERAPEUTICS INC Deferred State and Local Income Tax Expense (Benefit)
CORCEPT THERAPEUTICS INC (CORT) reported Deferred State and Local Income Tax Expense (Benefit) of -$3.51 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC deferred state and local income tax expense (benefit) for fiscal 2025 was -$3.51M.
- CORCEPT THERAPEUTICS INC deferred state and local income tax expense (benefit) for fiscal 2024 was -$3.78M.
- CORCEPT THERAPEUTICS INC deferred state and local income tax expense (benefit) for fiscal 2023 was -$2.65M.
- CORCEPT THERAPEUTICS INC deferred state and local income tax expense (benefit) for fiscal 2022 was -$5.31M.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$3.51M 10-K · filed 2026-02-24 |
| 2024-12-31 | -$3.78M 10-K · filed 2026-02-24 |
| 2023-12-31 | -$2.65M 10-K · filed 2026-02-24 |
| 2022-12-31 | -$5.31M 10-K · filed 2025-02-26 |
| 2021-12-31 | -$274.00K 10-K · filed 2024-02-15 |
| 2020-12-31 | $520.00K 10-K · filed 2023-02-28 |
| 2019-12-31 | $935.00K 10-K · filed 2022-02-15 |
| 2018-12-31 | -$176.00K 10-K · filed 2021-02-23 |
| 2017-12-31 | -$4.87M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |